Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer
Ryan Blawski(Sidney Kimmel Comprehensive Cancer Center), Eneda Toska(Johns Hopkins University)
Cited by 13
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k